Pharmion buys Cabrellis for $59 million
17th Nov 2006, 02:30 GMT
Pharmion Corporation has purchased private oncology company Cabrellis, which holds the US and EU rights to lung cancer drug amrubicin, for $59 million.
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol